Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease

INTRODUCTION: Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period. CASE PRESENTATION: We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine. CONCLU...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Qian-Ya, Zhang, Xiao-Dong, Hu, Ze-Di, Huang, Shi-Shi, Zhu, Shi-Guo, Chen, Cai-Ping, Zhang, Xiong, Wang, Jian-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561359/
https://www.ncbi.nlm.nih.gov/pubmed/36247788
http://dx.doi.org/10.3389/fneur.2022.961758
_version_ 1784807936017563648
author Fan, Qian-Ya
Zhang, Xiao-Dong
Hu, Ze-Di
Huang, Shi-Shi
Zhu, Shi-Guo
Chen, Cai-Ping
Zhang, Xiong
Wang, Jian-Yong
author_facet Fan, Qian-Ya
Zhang, Xiao-Dong
Hu, Ze-Di
Huang, Shi-Shi
Zhu, Shi-Guo
Chen, Cai-Ping
Zhang, Xiong
Wang, Jian-Yong
author_sort Fan, Qian-Ya
collection PubMed
description INTRODUCTION: Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period. CASE PRESENTATION: We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine. CONCLUSION: The current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.
format Online
Article
Text
id pubmed-9561359
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95613592022-10-15 Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease Fan, Qian-Ya Zhang, Xiao-Dong Hu, Ze-Di Huang, Shi-Shi Zhu, Shi-Guo Chen, Cai-Ping Zhang, Xiong Wang, Jian-Yong Front Neurol Neurology INTRODUCTION: Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period. CASE PRESENTATION: We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine. CONCLUSION: The current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements. Frontiers Media S.A. 2022-09-30 /pmc/articles/PMC9561359/ /pubmed/36247788 http://dx.doi.org/10.3389/fneur.2022.961758 Text en Copyright © 2022 Fan, Zhang, Hu, Huang, Zhu, Chen, Zhang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Fan, Qian-Ya
Zhang, Xiao-Dong
Hu, Ze-Di
Huang, Shi-Shi
Zhu, Shi-Guo
Chen, Cai-Ping
Zhang, Xiong
Wang, Jian-Yong
Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
title Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
title_full Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
title_fullStr Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
title_full_unstemmed Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
title_short Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
title_sort case report: blepharospasm in peak-dose dyskinesia may benefit from amantadine in parkinson's disease
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561359/
https://www.ncbi.nlm.nih.gov/pubmed/36247788
http://dx.doi.org/10.3389/fneur.2022.961758
work_keys_str_mv AT fanqianya casereportblepharospasminpeakdosedyskinesiamaybenefitfromamantadineinparkinsonsdisease
AT zhangxiaodong casereportblepharospasminpeakdosedyskinesiamaybenefitfromamantadineinparkinsonsdisease
AT huzedi casereportblepharospasminpeakdosedyskinesiamaybenefitfromamantadineinparkinsonsdisease
AT huangshishi casereportblepharospasminpeakdosedyskinesiamaybenefitfromamantadineinparkinsonsdisease
AT zhushiguo casereportblepharospasminpeakdosedyskinesiamaybenefitfromamantadineinparkinsonsdisease
AT chencaiping casereportblepharospasminpeakdosedyskinesiamaybenefitfromamantadineinparkinsonsdisease
AT zhangxiong casereportblepharospasminpeakdosedyskinesiamaybenefitfromamantadineinparkinsonsdisease
AT wangjianyong casereportblepharospasminpeakdosedyskinesiamaybenefitfromamantadineinparkinsonsdisease

Ejemplares similares